EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
- Abivax appoints Ana Sharma as Vice President, Global Head of Quality
The issuer is solely responsible for the content of this announcement. - Abivax appoints Ana Sharma as Vice President, Global Head of Quality
PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. - Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
- If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.